艾昆纬-2000-2022年药品支出动态

Understanding Medicine and Healthcare Spending in Context Introduction The level of drug expenditure is a closely watched, often commented upon,metric that has faced increased scrutiny by policymakers and other stakeholders Despite this, the composition of that expenditureand its dynamics are not well understood. Typically,official statistics of drug spending only include drugs The research for this report was undertakenindependently by the IQVIA Institute with the supportof the Association of the British Pharmaceutical Industry In October 2021, the IQVIA Institute published areport titled ‘Drug Expenditure Dynamics 1995–2020’with estimates of total drug spending, includinghospitals and net of discounts and rebates paid bypharmaceutical companies.i Almost four years on from Find Out More If you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list, MURRAY AITKEN Executive Director REFERENCING THIS REPORTPlease use this format when referencing content from this report: Source: IQVIA Institute for Human Data Science. Report: Drug Expenditure Dynamics 2000–2022: Understanding Medicine and HealthcareSpending in Context. October 2025. Available from www.iqviainstitute.org ©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without Overview Understanding components of drug expenditure Total drug expenditure is the most meaningful metric3Public sources have incomplete data on total drug expenditure4 Drug expenditure dynamics Total drug spending remains an important but small part of total healthcare expenditure6Drug spending as a share of healthcare continues to converge around 15%8Health spending often fluctuates but has risen more than drug spending8 Methodologies About the authors13 Overview Making cross-country comparisons of healthcare anddrug expenditure has become central to many policydiscussions over many years and importantly requires healthcare expenditure and is continuing to converge ataround 15%, with variation across the 12 global markets Countries with the highest drug share of healthexpenditure often have the lowest overall healthspend, while those with the lowest drug share havedemonstrated consistent commitments to market accesscontrols and drug price negotiation. The 15% unweightedaverage across 12 countries is the same as the U.S. The World Health Organization System of HealthAccounts (SHA) provides a robust measurement ofhealth spending, while the Organisation for EconomicCo-operation and Development (OECD) provides robustmeasurement of net drug expenditures through The key areas where official statistics are inconsistent orincomplete are related to non-retail drug spending, whichare not included in OECD reporting, and some countries Notable variations in the approval, availability anduse of novel medicines, along with pricing differencesacross countries, are understood to be among the most Overall, these analyses provide useful additional contextfor policy discussions, but do not provide the necessarybasis to determine whether individual countries’ drugspending is optimal. There are significant variations incountry health system structures, priorities, populationhealth needs, and economic resources, all of which may In some countries the official reported net drugexpenditure does not reflect all the discounts andrebates received by their governments, especially ifthose are post-hoc agreed industry re-payments, suchas the Voluntary Scheme for Branded Medicines Pricing, Overall, the analyses continue to show that drugexpenditure has remained a stable proportion of Understanding components of drug expenditure TOTAL DRUG EXPENDITURE IS THE MOST single-payer system, the National Health Service (NHS).Therefore, assessing specific segments in isolation(e.g., government funded expenditure only) does not Country health systems are heterogeneous and differin their approach to the provision, financing, andconsumption of pharmaceuticals. For instance, whilethe non-retail segment has been a growing portion of To ensure comparability across a diverse range of globalmarkets, this study evaluates “total drug expenditure.”This is inclusive of all medicines (prescription bound,over the counter, vaccines), all channels (retail, hospital),and all financing types (public, private, out of pocket),measured at public prices (inclusive of supply chain Furthermore, medicines are often financed differentlydepending on the structure of the national healthcaresystem. For example, private funding of medicines PUBLIC SOURCES HAVE INCOMPLETE DATA ON TOTAL OECD has attempted to address the lack of non-retailexpenditure data via a newer method of reporting(“total pharmaceutical sales”)3, but has